Octagon Capital Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-499,996
| Closed | -$8.59M | – | 42 |
|
|
2023
Q1 | $8.59M | Hold |
499,996
| – | – | 1.24% | 16 |
|
|
2022
Q4 | $11.1M | Hold |
499,996
| – | – | 1.73% | 15 |
|
|
2022
Q3 | $4.02M | Sell |
499,996
-132,749
| -21% | -$1.07M | 0.69% | 23 |
|
|
2022
Q2 | $4.42M | Sell |
632,745
-934,150
| -60% | -$6.52M | 1.18% | 13 |
|
|
2022
Q1 | $23.7M | Buy |
1,566,895
+15,825
| +1% | +$239K | 5.12% | 4 |
|
|
2021
Q4 | $34M | Buy |
1,551,070
+719,803
| +87% | +$15.8M | 6.62% | 4 |
|
|
2021
Q3 | $22.4M | Hold |
831,267
| – | – | 5.52% | 6 |
|
|
2021
Q2 | $20M | Buy |
831,267
+452,979
| +120% | +$10.9M | 4.15% | 6 |
|
|
2021
Q1 | $16.4M | Buy |
378,288
+511
| +0.1% | +$22.2K | 6.18% | 4 |
|
|
2020
Q4 | $15.7M | Buy |
+377,777
| New | +$15.7M | 5.43% | 5 |
|